Karen Bergman, VP of Communications and Investor Relations at Bolt Biotherapeutics, drives strategic narratives for the US HealthTech firm. Her expertise builds recognition for Bolt’s innovation in immuno-oncology, developing Boltbody ISACs to combat tumors and create lasting immunological memory. Bergman’s leadership enhances corporate reputation and investor engagement, guiding companies from private to public stages.
666 3rd Ave, 6th Floor, New York, NY 10017